FDA Approves ‘Jakafi’ A New Drug To Treat Polycythemia Vera

December 6, 2014 6:31 AM

12 0

Yesterday the FDA approved Jakafi (Ruxolitinib), a pill, for use in treating polycythemia vera. The drug, a targeted kinase inhibitor manufactured by Incyte, offers a needed option for some people affected by this serious blood disorder, a type of myeloproliferative disease.

Considered a rare disease, polycythemia vera affects about 50 in 100,000 (i.e. 1 in 2,000 adults) in the United States. It’s among conditions hematologists evaluate and treat fairly often. For reasons unknown, p. vera affects men more often than women. Almost all cases occur in older people; two-thi...

Read more

To category page